USA flag logo/image

An Official Website of the United States Government

Development of a Recombinant Subunit Ebola Vaccine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85253
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
AI066616
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PANTHERA BIOPHARMA, LLC
PANTHERA BIOPHARMA, LLC 99-193 AIEA HEIGHTS DR, STE 136 AIEA, HI 96701
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Development of a Recombinant Subunit Ebola Vaccine
Agency: HHS
Contract: 1R43AI066616-01A2
Award Amount: $959,998.00
 

Abstract:

DESCRIPTION (provided by applicant): Ebola and Marburg viruses, the only members of the family Filoviridae, cause hemorrhagic fevers which are lethal in up to 90% of human cases. No vaccine or antiviral therapy currently exists to prevent or treat Filoviru s infection. Due to their exceptional lethality and potential for weaponization, these viruses have been identified as key biodefense targets in both Project Bioshield and the NIAID Biodefense Research agenda. Hawaii Biotech, Inc. has successfully produced several recombinant Ebola virus proteins which show strong immunogenicity and protective efficacy in mice. The specific goals of this project are to expand the antigenic repertoire of the vaccine candidate to induce broad protection against both Ebola and Marburg viruses, to confirm the protective efficacy of the vaccine formulations in guinea pig and non-human primate models, and to ready the product for preclinical development in Phase II. The challenge studies will represent the preclinical proof of con cept for the approach, while the inclusion of additional glycoproteins will ensure that the vaccine candidate induces broad protective immunity against the most pathogenic Filovirus strains. The vaccine candidate has potential as a stand alone or as a part ner in a prime-boost approach in combination with other vaccine candidates currently being developed by the NIAID Vaccine Research Center. A safe and efficacious vaccine utilizing recombinant subunit proteins would fill an important need in the country's b iodefense preparedness strategy.

Principal Investigator:

Axel T. Lehrer
8084571458
ALEHRER@PANTHERABIO.COM

Business Contact:

Will Alameida
mjansson@pantherabio.com
Small Business Information at Submission:

PANTHERA BIOPHARMA, LLC
PANTHERA BIOPHARMA, LLC 99-193 AIEA HEIGHTS DR, STE 136 AIEA, HI 96701

EIN/Tax ID: 120531070
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No